GlassScriptPhysician profile
Elizabeth Arambula
NPI 1891483863
$2,201.47
in general payments reported to CMS, 2019-2025
36 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $514 · 2024: $665 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $166.39 | 2024-2025 | Besremi |
| Merck Sharp & Dohme LLC | $159.42 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $144.49 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Genmab U.S., INC. | $127.25 | 2023-2025 | Epkinly |
| Incyte Corporation | $122.85 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Sobi, INC | $109.12 | 2025 | |
| Puma Biotechnology, INC. | $108.58 | 2023-2024 | Nerlynx |
| Seagen INC. | $102.77 | 2023 | Adcetris, Padcev |
| Janssen Biotech, INC. | $94.99 | 2024-2025 | Rybrevant, Tecvayli, Talvey |
| Stemline Therapeutics INC. | $92.81 | 2025 | Orserdu, Elzonris |
| Astrazeneca Pharmaceuticals LP | $84.73 | 2024-2025 | Tagrisso, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $70.19 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $68.95 | 2023-2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $64.18 | 2025 | Iclusig |
| Glaxosmithkline, LLC. | $55.41 | 2025 | Ojjaara |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $54.87 | 2025 | Onivyde |
| Tersera Therapeutics LLC | $52.42 | 2023 | Zoladex |
| Taiho Oncology, INC. | $49.20 | 2024-2025 | |
| Scpharmaceuticals INC. | $48.07 | 2024 | |
| Abbvie INC. | $43.09 | 2025 | |
| Pharmacosmos Therapeutics INC. | $37.55 | 2025 | Monoferric |
| Geron Corporation | $31.29 | 2025 | Rytelo |
| Genentech USA, INC. | $27.37 | 2023 | Venclexta |
| Jazz Pharmaceuticals INC. | $27.05 | 2024 | |
| Janssen Pharmaceuticals, INC | $26.33 | 2023 | Invega Sustenna, Invega Trinza |
| Ge Healthcare | $25.25 | 2025 | |
| Tempus Ai, INC | $24.73 | 2024 | |
| Eisai INC. | $24.40 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $23.52 | 2025 | Lynozyfic |
| Alexion Pharmaceuticals, INC. | $23.48 | 2025 | Ultomiris |
| Emd Serono, INC. | $20.93 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.30 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.04 | 2023 | |
| Pfizer INC. | $17.89 | 2025 | |
| Iovance Biotherapeutics, INC. | $17.57 | 2025 | Amtagvi |
| Agios Pharmaceuticals, INC. | $15.99 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Arambula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.